Pendapatan perusahaan Gracell Biotechnologies Inc. (GRCL)

High utilization of automated sterile laboratories provides a stable production base for Gracell Biotechnologies (GRCL). The company's commercial revenue trend on the current GURU.Markets platform chart reflects dynamics where 0.00 is the current value of the indicator. Growth is supported by strategic R&D partnerships with clinics, while business success depends on the safety of genetic modifications and the precision of CAR-T therapy clinical trials.

GRCL - Dodolan perusahaan Gracell ing rentang 04.07.2022 - 03.03.2024

Rincian metrik komprehensif lan analitis Gracell Biotechnologies Inc. (GRCL)

- rega pasar lan target rega analis:

Rega bursa Gracell|GRCL - Bagan rega target

- rincian kapitalisasi pasar:

Nilai pasar Gracell Biotechnologies Inc.|GRCL - Nilai Total Perusahaan

- informasi kapitalisasi buku:

Aset Bersih saben Siji Saham Gracell Biotechnologies|GRCL - Aset Bersih Perusahaan|Nilai Pasar marang Nilai Buku gracellbio.com|GRCL - Total Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Rasio Utang marang Modal Gracell Biotechnologies|GRCL - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Gracell Bio|GRCL - Utang perusahaan|Rasio utang marang nilai buku Gracell Biotechnologies Inc.|GRCL - Utang jangka dawa perusahaan|Utang jangka cendhak Gracell Biotechnologies|Rasio jangkoan perantara gracellbio.com

- statistik bathi lan rasio pasar:

GRCL - Penghasilan resik|Bathi resik mangsa ngarep Gracell Biotechnologies|GRCL - Pangali P/E|Pangali mangsa ngarep rega marang bathi gracellbio.com|GRCL - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Gracell Biotechnologies Inc.|GRCL - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Gracell Biotechnologies|GRCL - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan gracellbio.com|GRCL - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Gracell Biotechnologies

- rincian pendapatan lan dodolan emiten:

GRCL - Dodolan perusahaan|Volume dodolan sing dikarepake perusahaan Gracell|GRCL - Multiplikator P/S|Prakiraan rega marang pendapatan Gracell Biotechnologies Inc.

Analisis komprehensif perusahaan:Gracell GRCL

A fundamental valuation of Gracell Biotechnologies (GRCL) requires a cash flow analysis to understand the sustainability of T-cell therapy development in China and the US. The daily volume of actual inflows reflected in the company's sales profile allows for the identification of business overheating risks by comparing current revenue with historical cycles to forecast a potential decline in the efficiency of the scientific portfolio within onco-hematology treatment.

Pesaing wigati